ACQUIRED · 2022
Who Acquired MagellenRx?
Prime Therapeutics · $1.35B· 11.8× EBITDA
The acquisition
MagellenRx was acquired by Prime Therapeutics in 2022 for $1.35B. The deal was priced at 11.8× EBITDA / 0.50× revenue.
MagellenRx at time of acquisition
Revenue
$2598.6M
EBITDA
$114.5M
Deal value
$1.35B
EV / EBITDA
11.8×
Similar pharmacy acquisitions
- University Compounding Pharmacy · acquired by Fagron in 2026 · $41.5M
- Choice Specialty Pharmacy Group · acquired by Better Choice Company, Inc. in 2025 · $28.0M
- Horizon Infusions · acquired by Rubicon in 2025 · $130.0M
- KabaFusion · acquired by Nautic Partners in 2025 · $2.20B
- Soleo Health · acquired by Court Square Capital and WindRose Health in 2025 · $1.10B
Run a valuation for a similar pharmacy business
Three fields, instant range, backed by 25,592 real M&A transactions including this one.
Open the pharmacy calculator →More on pharmacy valuations
- Value a medical practice
- Value a dental practice
- Value a veterinary practice
- Pharmacy valuation calculator· head-term variant
- Pharmacy median multiples· real-deal benchmarks
- How to value a pharmacy· long-form guide
Sourced from Press releases and SEC filings. Full deal page.
Citation: ExitValue.ai. (2022). MagellenRx acquired by Prime Therapeutics. https://exitvalue.ai/acquired/magellenrx